Cycle's Bid for Applied Therapeutics Stalls, Forcing Last-Minute Extension

CAMBRIDGE, England & DETROIT, MI – January 29, 2026 – The proposed acquisition of Applied Therapeutics by Cycle Group Holdings has hit a critical snag, forcing the UK-based pharmaceutical firm to grant a last-minute, 24-hour extension to its tender offer. The move came after Cycle failed to secure the necessary majority of shares from Applied Therapeutics stockholders by the original deadline, leaving the future of the financially distressed biotech company hanging precariously in the balance.

Cycle's subsidiary, AT2B, Inc., announced today that the offer, which was set to expire at 11:59 p.m. Eastern time on January 28, 2026, will now be extended until 11:59 p.m. on January 29, 2026. The brief extension underscores the urgency and uncertainty surrounding the deal, which is pivotal for both companies. For Cycle, it represents a key strategic expansion into the rare disease market. For Applied Therapeutics, it is potentially the only alternative to a complete liquidation.

A Race Against Time: The Numbers Behind the Stalemate

The core of the issue lies in the numbers. As of the initial deadline, only 44.32% of Applied Therapeutics' outstanding shares had been tendered, falling significantly short of the majority required for the deal to proceed. The offer on the table remains unchanged: $0.088 per share in cash, plus one non-tradeable contingent value right (CVR) per share.

This shortfall indicates a fractured or hesitant shareholder base, creating a high-stakes standoff. The condition for the offer's success is explicit: a majority of the then-outstanding shares of Applied's common stock must be tendered. Without crossing this threshold, the acquisition cannot move forward. Holders who have already tendered their shares are not required to take any further action, but the focus now shifts entirely to the holdouts who control the company's fate.

The extension, while short, provides a final, crucial window for undecided shareholders to act. However, it also amplifies the pressure on a company already facing significant financial headwinds. Applied Therapeutics' stock (NASDAQ: APLT) has plummeted nearly 83% over the past year, and the company reported a net loss of $62.1 million for the first nine months of 2025 with only $11.9 million in cash remaining as of September 30, 2025.

The High-Stakes Gamble for Shareholders

For Applied Therapeutics shareholders, the decision is a complex gamble with starkly different potential outcomes. The company's own Board of Directors has unanimously recommended that shareholders accept the offer, painting a grim picture of the alternative. In filings with the Securities and Exchange Commission, the board has warned that a failed tender offer would likely force the company to pursue liquidation, a scenario in which stockholders would probably receive no proceeds whatsoever.

Adding to this pressure is an $8.5 million promissory note Applied Therapeutics owes to Cycle, which carries a staggering 24% annual interest rate. The company has stated it would be unable to repay this debt if the acquisition collapses, further cementing the path toward insolvency. From the board's perspective, Cycle's offer is not just the best option; it is the only viable one.

Despite these dire warnings, a significant portion of shareholders are holding out. One likely reason is a perceived valuation gap. Applied Therapeutics' stock has been trading at approximately $0.096 per share, slightly above the cash portion of Cycle's offer. Furthermore, some analyst price targets sit as high as $0.25, feeding a narrative that the company's long-term potential, particularly its lead drug candidate govorestat, is being undervalued. This creates a powerful incentive for some to reject what they see as a lowball offer, betting that either a better deal will emerge or that the company's dire financial situation is overstated.

Deconstructing the Deal: The Ambiguity of the CVR

A central point of contention and uncertainty in the deal is the non-tradeable Contingent Value Right (CVR). While the cash portion of the offer is a mere $0.088 per share, the CVR offers the potential for up to an additional $0.40 per share. This value, however, is far from guaranteed.

The CVR payments are tied to a series of future regulatory and commercial milestones for Applied Therapeutics' pipeline products. These include:

• A payment of up to $0.10 upon FDA approval for a galactosemia indication within eight years.
• Another $0.10 upon FDA approval for a Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD) indication within eight years.
• Up to $0.20 if global net sales of a product reach $200 million within a four-quarter period within ten years.

For shareholders, the CVR represents a bet on Cycle's ability to successfully navigate the complex and expensive process of clinical trials, regulatory approval, and commercialization. Its non-tradeable nature means there is no market to sell the CVR; its value can only be realized if and when these specific, high-risk milestones are achieved. This long-term, uncertain payoff is likely seen as less attractive than immediate cash, especially for investors who are not positioned to wait years for a potential return that may never materialize.

A Strategic Imperative for Cycle Pharma

From Cycle's perspective, the acquisition is a calculated strategic move, not a speculative venture. Founded in 2012, the company has built its mission around serving patients in the rare disease community. Applied Therapeutics' pipeline aligns perfectly with this focus. Its lead candidate, govorestat, is an Aldose Reductase Inhibitor (ARI) being developed for several rare central nervous system metabolic diseases that currently have no FDA-approved treatments.

Successfully acquiring Applied Therapeutics would give Cycle control over a promising asset that fits directly into its core therapeutic areas, including metabolic and genetic conditions. This strategic alignment explains Cycle's persistence and its willingness to provide the bridge financing that now gives it significant leverage. The deal is less about acquiring a distressed company on the cheap and more about securing a pipeline that could generate significant long-term value and fulfill its corporate mission.

The final hours of the extended tender offer will be a tense period for all involved. The decision of a few remaining shareholders will determine whether Applied Therapeutics is integrated into Cycle's rare disease portfolio or faces a swift and unforgiving path to liquidation. The outcome will be known when the market opens, revealing whether the board's stark warnings or the hope for a higher valuation ultimately won the day.